We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| CRISPR Therapeutics AG | NASDAQ:CRSP | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 54.76 | 54.46 | 57.00 | 41 | 09:14:23 |
From Nov 2023 to May 2024
By Colin Kellaher
CRISPR Therapeutics and Vertex Pharmaceuticals have won Food and Drug Administration approval of their Casgevy gene therapy for sickle-cell disease, marking the first U.S. green light for a drug using the gene-editing technology known as Crispr.
The FDA on Friday said the approval covers Casgevy for the treatment of sickle-cell disease in patients 12 years of age and older with recurrent vaso-occlusive crises
U.K. regulators last month gave the world's first approval of Casgevy, granting conditional marketing authorization for the treatment of sickle-cell disease and transfusion-dependent beta thalassemia, a pair of inherited blood disorders.
An FDA decision on Casgevy in transfusion-dependent beta thalassemia is due by the end of March.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 08, 2023 11:31 ET (16:31 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year CRISPR Therapeutics Chart |
1 Month CRISPR Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
